Hypertension in Patients with Cancer

Souza, Vinícius Rodrigues de; Silva, Eduardo Nani; Ribeiro, Mário Luiz; Martins, Wolney de Andrade

doi:10.5935/abc.20150011

Cited by 52 publications

(52 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33 Cardiotoxicity of cancer treatment is an important concern, with a history of hypertension as a risk factor. A State of Science report on cancer treatment-related cardiotoxicity suggests a need for clinical assessment of cardiovascular risk prior to treatment initiation.…”

Section: Discussionmentioning

confidence: 99%

Cohort study of oncologic emergencies in patients with head and neck cancer

et al. 2017

View full text Add to dashboard Cite

Background Treatments for squamous cell carcinoma of the head and neck (HNSCC) are associated with toxicities that lead to emergency department (ED) presentation. Methods We utilized data from an ongoing prospective cohort of newly diagnosed, previously untreated patients (N=298) with HNSCC to evaluate the association between clinical and epidemiologic factors and risk and frequency of ED presentation. Time to event was calculated from the date of treatment initiation to ED presentation, date of death, or current date. Frequency of ED presentation was the sum of ED visits during the follow-up time. Results History of hypertension, normal/underweight body mass index (BMI), and probable depression predicted increased risk of ED presentation. BMI and severe pain were associated with higher frequency of ED presentation. Conclusions Clinical and epidemiologic factors can help predict HNSCC patients that will present to the ED to improve treatment-related patient outcomes and quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Cohort study of oncologic emergencies in patients with head and neck cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Both NSAID and corticosteroids are commonly used in this population and might result in retention of sodium and water through either inhibition of renal prostaglandins (NSAID) or as a consequence of elevated blood cortisol (corticosteroids) . The effect on SBP and proteinuria might be variable and depend on dose and dosing schedule.…”

Section: Discussionmentioning

confidence: 99%

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

Tjostheim

Stepien

Markovic

et al. 2016

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundSystemic hypertension and proteinuria are established adverse effects of tyrosine kinase inhibitor treatment in people.ObjectiveThe objective of this study was to investigate changes in systolic blood pressure and the incidence of proteinuria secondary to treatment with toceranib phosphate in dogs with cancer.AnimalsTwenty‐six control dogs and 30 dogs with cancer were evaluated for the first part of the study (baseline characteristics). For the second part (effect of toceranib phosphate treatment), 48 client‐owned dogs were evaluated, including 20 control dogs and 28 dogs with various types of neoplasia.MethodsProspective cohort study. Client‐owned healthy control dogs and dogs with cancer were enrolled. Blood pressure and urine protein:creatinine ratios were measured before treatment and 2 weeks after initiation of toceranib phosphate treatment.ResultsSystolic blood pressure was significantly (P = 0.0013) higher in previously normotensive treatment dogs after initiation of treatment with toceranib phosphate (152 mmHg ± 19) compared to baseline (136 mmHg ± 14). 37% of treated dogs developed SBP ≥ 160 mmHg. The prevalence of systemic hypertension (37%) and proteinuria (21%) at baseline in treatment dogs did not differ from that of age‐matched healthy controls (15% [P = 0.13] and 0% [P = 0.069], respectively).Conclusions and Clinical ImportanceToceranib phosphate treatment might result in increased systolic blood pressures in dogs. Systemic hypertension should be considered a potential adverse effect of this drug in dogs. Systemic hypertension and proteinuria were detected at clinically relevant frequencies in the dogs with cancer before antineoplastic therapies suggesting that monitoring of these variables might be warranted in this population.

show abstract

“… Table 1 is a comparative summary of the reported significant prohypertensive effects of several classes of oncology chemotherapeutic drugs including anthracyclines. Therefore, in addition to anthracyclines, special attention should also be paid to many other classes of anticancer drugs that are known to have high risks for drug-induced or exacerbated hypertension, especially, the angiogenesis inhibitors, including vascular endothelial growth factor (VEGF) inhibitors and tyrosine kinase inhibitors, which were discussed in detail in several recent review articles [2, 23, 25]. …”

Section: Hypertension and Exacerbation Of Aicmentioning

confidence: 99%

Potential Therapeutic Strategies for Hypertension‐Exacerbated Cardiotoxicity of Anticancer Drugs

Kuriakose

Kukreja

2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Despite their recognized cardiotoxic effects, anthracyclines remain an essential component in many anticancer regimens due to their superior antitumor efficacy. Epidemiologic data revealed that about one-third of cancer patients have hypertension, which is the most common comorbidity in cancer registries. The purpose of this review is to assess whether anthracycline chemotherapy exacerbates cardiotoxicity in patients with hypertension. A link between hypertension comorbidity and anthracycline-induced cardiotoxicity (AIC) was first suggested in 1979. Subsequent preclinical and clinical studies have supported the notion that hypertension is a major risk factor for AIC, along with the cumulative anthracycline dosage. There are several common or overlapping pathological mechanisms in AIC and hypertension, such as oxidative stress. Current evidence supports the utility of cardioprotective modalities as adjunct treatment prior to and during anthracycline chemotherapy. Several promising cardioprotective approaches against AIC pathologies include dexrazoxane, early hypertension management, and dietary supplementation of nitrate with beetroot juice or other medicinal botanical derivatives (e.g., visnagin and Danshen), which have both antihypertensive and anti-AIC properties. Future research is warranted to further elucidate the mechanisms of hypertension and AIC comorbidity and to conduct well-controlled clinical trials for identifying effective clinical strategies to improve long-term prognoses in this subgroup of cancer patients.

show abstract

Hypertension in Patients with Cancer

Cited by 52 publications

References 38 publications

Cohort study of oncologic emergencies in patients with head and neck cancer

Cohort study of oncologic emergencies in patients with head and neck cancer

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

Potential Therapeutic Strategies for Hypertension‐Exacerbated Cardiotoxicity of Anticancer Drugs

Contact Info

Product

Resources

About